Cover Image
市場調查報告書

全身性肥胖細胞症:開發中產品分析

Systemic Mastocytosis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 253676
出版日期 內容資訊 英文 106 Pages
訂單完成後即時交付
價格
Back to Top
全身性肥胖細胞症:開發中產品分析 Systemic Mastocytosis - Pipeline Review, H2 2016
出版日期: 2016年11月16日 內容資訊: 英文 106 Pages
簡介

全身性肥大細胞增生症是肥胖細胞以骨髓為首在複數的器官中異常增生的疾病。伴隨有呼吸急促、低血壓,蕁麻疹,腫起、發癢、下痢、頭痛、發熱、肌肉或骨骼疼痛等症狀。治療有使用抗組織胺藥物,若是更具侵襲性的全身性肥大細胞增生症時,可使用干擾素和化療用醫藥品。

本報告提供全身性肥胖細胞症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

全身性肥胖細胞症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

全身性肥胖細胞症:企業開發中的治療藥

全身性肥胖細胞症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

全身性肥胖細胞症:企業開發中的產品

全身性肥胖細胞症的治療藥的開發企業

  • AB Science SA
  • AbbVie Inc.
  • Allakos Inc.
  • Arog Pharmaceuticals, Inc.
  • Blueprint Medicines Corporation
  • Bristol-Myers Squibb Company
  • Deciphera Pharmaceuticals, LLC
  • Novartis AG
  • Patara Pharma, Inc.
  • Stemline Therapeutics, Inc.

全身性肥胖細胞症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

全身性肥胖細胞症:最近的開發平台趨勢

全身性肥胖細胞症:開發中止的產品

全身性肥胖細胞症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8648IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Mastocytosis - Pipeline Review, H2 2016, provides an overview of the Systemic Mastocytosis (Gastrointestinal) pipeline landscape.

Systemic mastocytosis is a disorder where mast cells are abnormally increased in multiple organs including the bone marrow. Symptoms include shortness of breath, low blood pressure, hives and swelling, itching, diarrhea, headache, flushing and musculoskeletal pain. Treatment includes antihistamines and more aggressive forms of Systemic mastocytosis require interferon or chemotherapeutic agents.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Mastocytosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Systemic Mastocytosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Mastocytosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Systemic Mastocytosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 2, 4, 3 and 1 respectively.Systemic Mastocytosis.

Systemic Mastocytosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Mastocytosis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Systemic Mastocytosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Systemic Mastocytosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Systemic Mastocytosis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Systemic Mastocytosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Systemic Mastocytosis Overview
  • Therapeutics Development
    • Pipeline Products for Systemic Mastocytosis - Overview
  • Systemic Mastocytosis - Therapeutics under Development by Companies
  • Systemic Mastocytosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Systemic Mastocytosis - Products under Development by Companies
  • Systemic Mastocytosis - Companies Involved in Therapeutics Development
    • AB Science SA
    • AbbVie Inc
    • Allakos Inc.
    • Arog Pharmaceuticals, Inc.
    • Blueprint Medicines Corporation
    • Bristol-Myers Squibb Company
    • Deciphera Pharmaceuticals, LLC
    • Novartis AG
    • Patara Pharma Inc
    • Stemline Therapeutics, Inc.
  • Systemic Mastocytosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AK-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BLU-285 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • crenolanib besylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cromolyn sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dasatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DCC-2618 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ibrutinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • masitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • midostaurin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SL-401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Systemic Mastocytosis - Discontinued Products
  • Systemic Mastocytosis - Product Development Milestones
    • Featured News & Press Releases
      • Nov 03, 2016: Blueprint Medicines to Present Preliminary Data from Ongoing Phase 1 Clinical Trial for BLU-285 in Advanced Systemic Mastocytosis at 2016 ASH Annual Meeting
      • Oct 31, 2016: Deciphera Pharmaceuticals to Present Clinical Data on DCC-2618 at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
      • Oct 28, 2016: Blueprint Medicines to Present Preclinical Data and Provide Enrollment Updates for Phase 1 Clinical Trial for BLU-285 in Advanced Systemic Mastocytosis at ECNM Annual Meeting 2016
      • Sep 15, 2016: Allakos Begins Clinical Trials of AK002 in Patients with Systemic Mastocytosis
      • Jun 29, 2016: Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM)
      • May 30, 2016: AB Science will Present Phase 3 Data in Severe Systemic Mastocytosis at the International 21St Congress of the European Hematology Association
      • May 02, 2016: AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis
      • Feb 01, 2016: AB Science announces that Rapporteurs appointed by the EMA have recommended to file a marketing authorization application for full approval for masitinib in severe systemic mastocytosis
      • Dec 07, 2015: AB Science announces results from Phase 3 randomized placebo-controlled trial of masitinib in adults with severe systemic mastocytosis unresponsive to optimal symptomatic treatment
      • Nov 30, 2015: AB Science Announces Positive Top-Line Results from Phase 3 Trial of Masitinib in Adults with Severe Systemic Mastocytosis
      • Sep 10, 2015: Blueprint Medicines Receives FDA Authorization to Advance Novel Drug Candidate into Clinical Trial for Systemic Mastocytosis
      • Dec 08, 2014: Blueprint Medicines Debuts Comprehensive Preclinical Data Set on First Selective Drug for Patients with Systemic Mastocytosis at 2014 American Society of Hematology Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Systemic Mastocytosis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Systemic Mastocytosis - Pipeline by AB Science SA, H2 2016
  • Systemic Mastocytosis - Pipeline by AbbVie Inc, H2 2016
  • Systemic Mastocytosis - Pipeline by Allakos Inc., H2 2016
  • Systemic Mastocytosis - Pipeline by Arog Pharmaceuticals, Inc., H2 2016
  • Systemic Mastocytosis - Pipeline by Blueprint Medicines Corporation, H2 2016
  • Systemic Mastocytosis - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Systemic Mastocytosis - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2016
  • Systemic Mastocytosis - Pipeline by Novartis AG, H2 2016
  • Systemic Mastocytosis - Pipeline by Patara Pharma Inc, H2 2016
  • Systemic Mastocytosis - Pipeline by Stemline Therapeutics, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Systemic Mastocytosis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Systemic Mastocytosis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top